Rankings / Longevity — Supplements

Yamanaka factors / partial reprogramming

Longevity · Epigenetic reprogramming

Tier D

research-only
3.1 / 10
Tier D
Ev 2 Bn 5 Sf 3.5

Bottom line

Read Off Label grades Yamanaka factors / partial reprogramming as D (3.1/10) based on preclinical evidence, variable benefit magnitude, and a med-high-risk safety profile.

Ocampo 2016 Cell and subsequent Belmonte work show rejuvenation of aged tissues in mice via cyclic OSK expression.

Typical use: No approved human protocol — Research only.

What this is

Ocampo 2016 Cell and subsequent Belmonte work show rejuvenation of aged tissues in mice via cyclic OSK expression. Altos Labs ($3B+ funding) actively developing clinical protocols. No approved human therapy yet. A 2026 preclinical meta-analysis (14 studies) found epigenetic-clock (DNAmAge) reversal was NOT associated with functional improvement — a caution that "epigenomic rejuvenation" does not automatically mean restored function.

Mechanism

Transient expression of OCT4, SOX2, KLF4, MYC (or OSK without MYC) resets epigenetic age markers without inducing pluripotency; research-stage approach to reverse cellular aging

Dose & route

No approved human protocol

Common questions

Does Yamanaka factors / partial reprogramming work?
Read Off Label rates the evidence for Yamanaka factors / partial reprogramming as Preclinical and the benefit magnitude as variable, producing an overall grade of D (3.1/10). Ocampo 2016 Cell and subsequent Belmonte work show rejuvenation of aged tissues in mice via cyclic OSK expression.
Is Yamanaka factors / partial reprogramming safe?
Yamanaka factors / partial reprogramming has a med-high risk profile in published human data. Legal status: Research only. This is not medical advice — see the disclaimer.
What is the typical dose for Yamanaka factors / partial reprogramming?
No approved human protocol
How does Yamanaka factors / partial reprogramming work?
Transient expression of OCT4, SOX2, KLF4, MYC (or OSK without MYC) resets epigenetic age markers without inducing pluripotency; research-stage approach to reverse cellular aging

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.